Subcutaneous Administration of Recombinant Human Granulocyte Colony-stimulating Factor (KRN8601) in Intensive Chemotherapy for Patients with Advanced Lung Cancer
| Autor: | Tetsu Shinkai, Yuichiro Ohe, Masaaki Fukuda, Yasutsuna Sasaki, Nagahiro Saijo, Akira Kojima, Tomohide Tamura, Kazuhiko Nakagawa, Fumihiro Oshita, Keiichi Suemasu, Kouzou Yamada, Kenji Eguchi, Masashige Morita |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Lung Neoplasms Injections Subcutaneous medicine.medical_treatment Granulocyte Neutropenia Gastroenterology Article Leukocyte Count Carcinoma Non-Small-Cell Lung Internal medicine Antineoplastic Combined Chemotherapy Protocols Granulocyte Colony-Stimulating Factor medicine Chemotherapy Humans Carcinoma Small Cell Lung cancer Aged Lung Dose-Response Relationship Drug business.industry Respiratory disease Middle Aged medicine.disease Recombinant Proteins Surgery Granulocyte colony-stimulating factor medicine.anatomical_structure Oncology Injections Intravenous Toxicity Recombinant human granulocyte colony‐stimulating factor Female business |
| Zdroj: | Japanese Journal of Cancer Research : Gann |
| ISSN: | 0910-5050 |
| DOI: | 10.1111/j.1349-7006.1990.tb02530.x |
| Popis: | The efficacy and toxicity of recombinant human granulocyte colony-stimulating factor (rh G-CSF, KRN8601) given subcutaneously was evaluated in patients with advanced lung cancer undergoing intensive chemotherapy. Twenty-nine and 30 patients with or without prior therapy were enrolled in this study. At dose levels of 50, 90 and 130 micrograms/m2 of rh G-CSF for 14 consecutive days after chemotherapy, the mean neutrophil nadir counts, the mean neutrophil nadir ratios and the duration of neutropenia (days of less than 1000/mm3) were significantly improved. No significant differences were seen in frequency and duration of febrile episodes (greater than 38 degrees C). When rh G-CSF is given subcutaneously, the dose required for an equal effect in alleviating neutropenia is 50% of that required when it is given intravenously. The monocyte counts in the peripheral blood were also significantly increased after chemotherapy cycles with rh G-CSF. The cumulative plasma concentration of rh G-CSF showed a decrement after 7-9 days despite maintenance of the same dose of rh G-CSF for the entire 14 days. In conclusion, 50-130 micrograms/m2 of sc rh G-CSF increased the neutrophil nadir count and shortened the duration of neutropenia in patients undergoing intensive chemotherapy for lung cancer without intolerable side effects. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Plný text